Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00065676 · ClinicalTrials.gov registry record · Phase 2

Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes

A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Completed
Registry status
Phase 2
Development phase
24
Enrollment target

NCT00065676 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00065676, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target

Study Summary

Quercetin is a compound naturally found in various foods. It may have some role in the treatment of obesity and diabetes. The purpose of this study is to investigate research volunteers with obesity or obesity with type 2 diabetes to determine whether quercetin affects the way glucose is absorbed by the body. Thirty two participants aged 19 to 65 who are considered to be medically obese or obese with type 2 diabetes will be enrolled in this study. Before the onset of treatment, they will undergo a medical history, physical exam, blood work, and urinalysis. During the study, participants will be given an oral glucose tolerance test three times; during these tests they will receive 1 or 2 grams of quercetin, or placebo. Researchers will collect blood samples and analyze the effect of the treatment on blood glucose.

Interventions

  • OTHER Placebo
  • OTHER Quercetin

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2010-04-30
Est. Completion 2021-08-06
Phase Phase 2

What the Registry Record Tells You About NCT00065676

The ClinicalTrials.gov registry entry for NCT00065676 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00065676 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00065676 about?

NCT00065676 is a clinical study titled "Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes". Quercetin is a compound naturally found in various foods. It may have some role in the treatment of obesity and diabetes. The purpose of this study is to investigate research volunteers with obesity or obesity with type 2 diabetes to determine whether quercetin affects the way glucose is absorbed b...

What is the current status of trial NCT00065676?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-04-30. Estimated completion is 2021-08-06.

What interventions are being tested in trial NCT00065676?

The interventions under investigation include: Placebo (OTHER), Quercetin (OTHER).

Who is sponsoring clinical trial NCT00065676?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.